Details for New Drug Application (NDA): 210773
✉ Email this page to a colleague
NDA 210773 describes MEROPENEM, which is a drug marketed by Acs Dobfar, Acs Dobfar Spa, Amneal Pharms, Brooks Steriscience, Daewoong Pharm Co, Eugia Pharma, Gland, Hospira Inc, Hq Spclt Pharma, Qilu, Sandoz, Savior Lifetec Corp, and B Braun Medical Inc, and is included in fourteen NDAs. It is available from fourteen suppliers. Additional details are available on the MEROPENEM profile page.
The generic ingredient in MEROPENEM is meropenem. There are thirty-two drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the meropenem profile page.
The generic ingredient in MEROPENEM is meropenem. There are thirty-two drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the meropenem profile page.
Summary for 210773
| Tradename: | MEROPENEM |
| Applicant: | Hq Spclt Pharma |
| Ingredient: | meropenem |
| Patents: | 0 |
Suppliers and Packaging for NDA: 210773
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| MEROPENEM | meropenem | INJECTABLE;INJECTION | 210773 | ANDA | WG Critical Care, LLC | 44567-145 | 44567-145-10 | 10 VIAL in 1 CARTON (44567-145-10) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL (44567-145-01) |
| MEROPENEM | meropenem | INJECTABLE;INJECTION | 210773 | ANDA | WG Critical Care, LLC | 44567-146 | 44567-146-10 | 10 VIAL in 1 CARTON (44567-146-10) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL (44567-146-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 500MG/VIAL | ||||
| Approval Date: | Aug 16, 2019 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 1GM/VIAL | ||||
| Approval Date: | Aug 16, 2019 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
